Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 397 entries
Sorted by: Best Match Show Resources per page
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia.

JMIR mHealth and uHealth

Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, Hanina A.
PMID: 28223265
JMIR Mhealth Uhealth. 2017 Feb 21;5(2):e18. doi: 10.2196/mhealth.7030.

BACKGROUND: Accurately monitoring and collecting drug adherence data can allow for better understanding and interpretation of the outcomes of clinical trials. Most clinical trials use a combination of pill counts and self-reported data to measure drug adherence, despite the...

Cite
Bain EE, Shafner L, Walling DP, et al. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR Mhealth Uhealth. 2017;5(2):e18doi: 10.2196/mhealth.7030.
Bain, E. E., Shafner, L., Walling, D. P., Othman, A. A., Chuang-Stein, C., Hinkle, J., & Hanina, A. (2017). Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR mHealth and uHealth, 5(2), e18. https://doi.org/10.2196/mhealth.7030
Bain, Earle E, et al. "Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia." JMIR mHealth and uHealth vol. 5,2 (2017): e18. doi: https://doi.org/10.2196/mhealth.7030
Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, Hanina A. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR Mhealth Uhealth. 2017 Feb 21;5(2):e18. doi: 10.2196/mhealth.7030. PMID: 28223265; PMCID: PMC5340925.
Copy Download .nbib Format: NLM
Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case.

Molecular cytogenetics

Al-Achkar W, Moassass F, Ikhtiar A, Liehr T, Othman MA, Wafa A.
PMID: 25621010
Mol Cytogenet. 2014 Nov 29;7(1):89. doi: 10.1186/s13039-014-0089-0. eCollection 2014.

BACKGROUND: Chronic myeloid leukemia (CML) is genetically characterized by the occurrence of a reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22, i.e. the Philadelphia (Ph) chromosome. During CML progression 60-80% of the cases...

Cite
Al-Achkar W, Moassass F, Ikhtiar A, et al. Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. Mol Cytogenet. 2014;7(1):89doi: 10.1186/s13039-014-0089-0.
Al-Achkar, W., Moassass, F., Ikhtiar, A., Liehr, T., Othman, M. A., & Wafa, A. (2014). Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. Molecular cytogenetics, 7(1), 89. https://doi.org/10.1186/s13039-014-0089-0
Al-Achkar, Walid, et al. "Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case." Molecular cytogenetics vol. 7,1 (2014): 89. doi: https://doi.org/10.1186/s13039-014-0089-0
Al-Achkar W, Moassass F, Ikhtiar A, Liehr T, Othman MA, Wafa A. Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. Mol Cytogenet. 2014 Nov 29;7(1):89. doi: 10.1186/s13039-014-0089-0. eCollection 2014. PMID: 25621010; PMCID: PMC4305221.
Copy Download .nbib Format: NLM
Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.

PloS one

Attia SM, Ahmad SF, Ansaria MA, Nadeem A, Al-Shabanah OA, Al-Harbi MM, Bakheet SA.
PMID: 27690233
PLoS One. 2016 Sep 30;11(9):e0163703. doi: 10.1371/journal.pone.0163703. eCollection 2016.

Dexrazoxane has been approved to treat anthracycline-induced cardiomyopathy and extravasation. However, the effect of dexrazoxane on epirubicin-induced genetic alterations in germ cells has not yet been reported. Thus, the aim of this study was to determine whether dexrazoxane modulates...

Cite
Attia SM, Ahmad SF, Ansaria MA, et al. Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells. PLoS One. 2016;11(9):e0163703doi: 10.1371/journal.pone.0163703.
Attia, S. M., Ahmad, S. F., Ansaria, M. A., Nadeem, A., Al-Shabanah, O. A., Al-Harbi, M. M., & Bakheet, S. A. (2016). Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells. PloS one, 11(9), e0163703. https://doi.org/10.1371/journal.pone.0163703
Attia, Sabry M, et al. "Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells." PloS one vol. 11,9 (2016): e0163703. doi: https://doi.org/10.1371/journal.pone.0163703
Attia SM, Ahmad SF, Ansaria MA, Nadeem A, Al-Shabanah OA, Al-Harbi MM, Bakheet SA. Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells. PLoS One. 2016 Sep 30;11(9):e0163703. doi: 10.1371/journal.pone.0163703. eCollection 2016. PMID: 27690233; PMCID: PMC5045162.
Copy Download .nbib Format: NLM
Enhanced sulfur removal by a tuned composite structure of Cu, Zn, Fe, and Al elements.

Journal of hazardous materials

Zahid WM, Othman MA, Abasaeed AE.
PMID: 28273577
J Hazard Mater. 2017 Jun 05;331:273-279. doi: 10.1016/j.jhazmat.2017.02.050. Epub 2017 Feb 28.

Several combinations of high sulfur affinity elements of Cu, Zn, Fe, and Al were used to prepare sorbent materials that remove hydrogen sulfide (H

Cite
Zahid WM, Othman MA, Abasaeed AE. Enhanced sulfur removal by a tuned composite structure of Cu, Zn, Fe, and Al elements. J Hazard Mater. 2017;331:273-279doi: 10.1016/j.jhazmat.2017.02.050.
Zahid, W. M., Othman, M. A., & Abasaeed, A. E. (2017). Enhanced sulfur removal by a tuned composite structure of Cu, Zn, Fe, and Al elements. Journal of hazardous materials, 331273-279. https://doi.org/10.1016/j.jhazmat.2017.02.050
Zahid, Waleed Mohammad, et al. "Enhanced sulfur removal by a tuned composite structure of Cu, Zn, Fe, and Al elements." Journal of hazardous materials vol. 331 (2017): 273-279. doi: https://doi.org/10.1016/j.jhazmat.2017.02.050
Zahid WM, Othman MA, Abasaeed AE. Enhanced sulfur removal by a tuned composite structure of Cu, Zn, Fe, and Al elements. J Hazard Mater. 2017 Jun 05;331:273-279. doi: 10.1016/j.jhazmat.2017.02.050. Epub 2017 Feb 28. PMID: 28273577.
Copy Download .nbib Format: NLM
Targeted Cancer Therapy: Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity (Adv. Healthcare Mater. 11/2016).

Advanced healthcare materials

Othman BA, Greenwood C, Abuelela AF, Bharath AA, Chen S, Theodorou I, Douglas T, Uchida M, Ryan M, Merzaban JS, Porter AE.
PMID: 27275627
Adv Healthc Mater. 2016 Jun;5(11):1248. doi: 10.1002/adhm.201670053.

On page 1310 J. S. Merzaban, A. E. Porter, and co-workers present fluorescently labeled RGD-targeted ZnO nanoparticles (NPs; green) for the targeted delivery of cytotoxic ZnO to integrin αvβ3 receptors expressed on triple negative breast cancer cells. Correlative light-electron...

Cite
Othman BA, Greenwood C, Abuelela AF, et al. Targeted Cancer Therapy: Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity (Adv. Healthcare Mater. 11/2016). Adv Healthc Mater. 2016;5(11):1248doi: 10.1002/adhm.201670053.
Othman, B. A., Greenwood, C., Abuelela, A. F., Bharath, A. A., Chen, S., Theodorou, I., Douglas, T., Uchida, M., Ryan, M., Merzaban, J. S., & Porter, A. E. (2016). Targeted Cancer Therapy: Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity (Adv. Healthcare Mater. 11/2016). Advanced healthcare materials, 5(11), 1248. https://doi.org/10.1002/adhm.201670053
Othman, Basmah A, et al. "Targeted Cancer Therapy: Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity (Adv. Healthcare Mater. 11/2016)." Advanced healthcare materials vol. 5,11 (2016): 1248. doi: https://doi.org/10.1002/adhm.201670053
Othman BA, Greenwood C, Abuelela AF, Bharath AA, Chen S, Theodorou I, Douglas T, Uchida M, Ryan M, Merzaban JS, Porter AE. Targeted Cancer Therapy: Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity (Adv. Healthcare Mater. 11/2016). Adv Healthc Mater. 2016 Jun;5(11):1248. doi: 10.1002/adhm.201670053. PMID: 27275627.
Copy Download .nbib Format: NLM
Erratum.

Molecular genetics & genomic medicine

Wincent J, Luthman A, van Belzen M, van der Lans C, Albert J, Nordgren A, Anderlid BM.
PMID: 27247963
Mol Genet Genomic Med. 2016 May 12;4(3):367. doi: 10.1002/mgg3.218. eCollection 2016 May.

[This corrects the article DOI: 10.1002/mgg3.177.].

Cite
Wincent J, Luthman A, van Belzen M, et al. Erratum. Mol Genet Genomic Med. 2016;4(3):367doi: 10.1002/mgg3.218.
Wincent, J., Luthman, A., van Belzen, M., van der Lans, C., Albert, J., Nordgren, A., & Anderlid, B. M. (2016). Erratum. Molecular genetics & genomic medicine, 4(3), 367. https://doi.org/10.1002/mgg3.218
Wincent, Josephine, et al. "Erratum." Molecular genetics & genomic medicine vol. 4,3 (2016): 367. doi: https://doi.org/10.1002/mgg3.218
Wincent J, Luthman A, van Belzen M, van der Lans C, Albert J, Nordgren A, Anderlid BM. Erratum. Mol Genet Genomic Med. 2016 May 12;4(3):367. doi: 10.1002/mgg3.218. eCollection 2016 May. PMID: 27247963; PMCID: PMC4867569.
Copy Download .nbib Format: NLM
Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs.

Clinical drug investigation

Sommerville KW, Dutta S, Biton V, Zhang Y, Cloyd JC, Uthman B.
PMID: 17535081
Clin Drug Investig. 2003;23(10):661-70. doi: 10.2165/00044011-200323100-00005.

OBJECTIVES: To compare the bioavailability of divalproex extended release (divalproex-ER) given once daily relative to the conventional divalproex formulation given once every 8 hours, using various divalproex-ER doses that are 8-20% greater than the corresponding divalproex total daily doses.DESIGN...

Cite
Sommerville KW, Dutta S, Biton V, et al. Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs. Clin Drug Investig. 2003;23(10):661-70doi: 10.2165/00044011-200323100-00005.
Sommerville, K. W., Dutta, S., Biton, V., Zhang, Y., Cloyd, J. C., & Uthman, B. (2003). Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs. Clinical drug investigation, 23(10), 661-70. https://doi.org/10.2165/00044011-200323100-00005
Sommerville, Kenneth W, et al. "Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs." Clinical drug investigation vol. 23,10 (2003): 661-70. doi: https://doi.org/10.2165/00044011-200323100-00005
Sommerville KW, Dutta S, Biton V, Zhang Y, Cloyd JC, Uthman B. Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs. Clin Drug Investig. 2003;23(10):661-70. doi: 10.2165/00044011-200323100-00005. PMID: 17535081.
Copy Download .nbib Format: NLM
3-Methyl-2-propionamido-butanoic acid.

Acta crystallographica. Section E, Structure reports online

Yamin BM, Othman EA.
PMID: 21582407
Acta Crystallogr Sect E Struct Rep Online. 2009 Mar 06;65:o662. doi: 10.1107/S1600536809007119.

The reaction of propionyl isothio-cyanate with valine was found to give the title compound, C(8)H(15)NO(3), instead of the expected thio-urea product. The whole mol-ecule is non-planar and the carbonyl group is cis to the methyl-butanoic acid group across the...

Cite
Yamin BM, Othman EA. 3-Methyl-2-propionamido-butanoic acid. Acta Crystallogr Sect E Struct Rep Online. 2009;65:o662doi: 10.1107/S1600536809007119.
Yamin, B. M., & Othman, E. A. (2009). 3-Methyl-2-propionamido-butanoic acid. Acta crystallographica. Section E, Structure reports online, 65o662. https://doi.org/10.1107/S1600536809007119
Yamin, Bohari M, and Othman, Eliyanti A. "3-Methyl-2-propionamido-butanoic acid." Acta crystallographica. Section E, Structure reports online vol. 65 (2009): o662. doi: https://doi.org/10.1107/S1600536809007119
Yamin BM, Othman EA. 3-Methyl-2-propionamido-butanoic acid. Acta Crystallogr Sect E Struct Rep Online. 2009 Mar 06;65:o662. doi: 10.1107/S1600536809007119. PMID: 21582407; PMCID: PMC2968931.
Copy Download .nbib Format: NLM
Acquired del(9)(p22.3) in a primary plasma cell leukemia.

Molecular cytogenetics

Achkar WA, Wafa A, Aljapawe A, Othman MA, Alhourani E, Liehr T.
PMID: 23985162
Mol Cytogenet. 2013 Aug 28;6(1):33. doi: 10.1186/1755-8166-6-33.

BACKGROUND: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder, accounting for 1-2% of all plasma cell neoplasms, characterized by the presence of >2 × 109/l of plasma cells circulating in the peripheral blood, and exists in two forms:...

Cite
Achkar WA, Wafa A, Aljapawe A, et al. Acquired del(9)(p22.3) in a primary plasma cell leukemia. Mol Cytogenet. 2013;6(1):33doi: 10.1186/1755-8166-6-33.
Achkar, W. A., Wafa, A., Aljapawe, A., Othman, M. A., Alhourani, E., & Liehr, T. (2013). Acquired del(9)(p22.3) in a primary plasma cell leukemia. Molecular cytogenetics, 6(1), 33. https://doi.org/10.1186/1755-8166-6-33
Achkar, Walid Al, et al. "Acquired del(9)(p22.3) in a primary plasma cell leukemia." Molecular cytogenetics vol. 6,1 (2013): 33. doi: https://doi.org/10.1186/1755-8166-6-33
Achkar WA, Wafa A, Aljapawe A, Othman MA, Alhourani E, Liehr T. Acquired del(9)(p22.3) in a primary plasma cell leukemia. Mol Cytogenet. 2013 Aug 28;6(1):33. doi: 10.1186/1755-8166-6-33. PMID: 23985162; PMCID: PMC3765975.
Copy Download .nbib Format: NLM
Cryphodera utahensis n. sp., (Heteroderidae), A New Species from Wild Rose in Utah.

Journal of nematology

Baldwin JG, Mundo-Ocampo M, Othman AA.
PMID: 19295789
J Nematol. 1983 Apr;15(2):182-91.

A new species of Cryphodera Colbran, 1966, parasitic on wild rose (Rosa sp. L.), is described from Utah, USA. Cryphodera utahensis n. sp. most closely resembles C. podocarpi (Wouts, 1973) Luc et al., 1978, but is distinct with respect...

Cite
Baldwin JG, Mundo-Ocampo M, Othman AA. Cryphodera utahensis n. sp., (Heteroderidae), A New Species from Wild Rose in Utah. J Nematol. 1983;15(2):182-91
Baldwin, J. G., Mundo-Ocampo, M., & Othman, A. A. (1983). Cryphodera utahensis n. sp., (Heteroderidae), A New Species from Wild Rose in Utah. Journal of nematology, 15(2), 182-91.
Baldwin, J G, et al. "Cryphodera utahensis n. sp., (Heteroderidae), A New Species from Wild Rose in Utah." Journal of nematology vol. 15,2 (1983): 182-91.
Baldwin JG, Mundo-Ocampo M, Othman AA. Cryphodera utahensis n. sp., (Heteroderidae), A New Species from Wild Rose in Utah. J Nematol. 1983 Apr;15(2):182-91. PMID: 19295789; PMCID: PMC2618276.
Copy Download .nbib Format: NLM
A Preliminary Study on the Reliability of the Malay Version of PedsQL™ Family Impact Module among Caregivers of Children with Disabilities in Kelantan, Malaysia.

The Malaysian journal of medical sciences : MJMS

Rahman AA, Mohamad N, Imran MK, Ibrahim WP, Othman A, Aziz AA, Harith S, Ibrahim MI, Ariffin NH, Van Rostenberghe H.
PMID: 22589674
Malays J Med Sci. 2011 Oct;18(4):63-8.

BACKGROUND: No previous study has assessed the impact of childhood disability on parents and family in the context of Malaysia, and no instrument to measure this impact has previously been available. The objective of this cross-sectional study was to...

Cite
Rahman AA, Mohamad N, Imran MK, et al. A Preliminary Study on the Reliability of the Malay Version of PedsQL™ Family Impact Module among Caregivers of Children with Disabilities in Kelantan, Malaysia. Malays J Med Sci. 2011;18(4):63-8
Rahman, A. A., Mohamad, N., Imran, M. K., Ibrahim, W. P., Othman, A., Aziz, A. A., Harith, S., Ibrahim, M. I., Ariffin, N. H., & Van Rostenberghe, H. (2011). A Preliminary Study on the Reliability of the Malay Version of PedsQL™ Family Impact Module among Caregivers of Children with Disabilities in Kelantan, Malaysia. The Malaysian journal of medical sciences : MJMS, 18(4), 63-8.
Rahman, Azriani Ab, et al. "A Preliminary Study on the Reliability of the Malay Version of PedsQL™ Family Impact Module among Caregivers of Children with Disabilities in Kelantan, Malaysia." The Malaysian journal of medical sciences : MJMS vol. 18,4 (2011): 63-8.
Rahman AA, Mohamad N, Imran MK, Ibrahim WP, Othman A, Aziz AA, Harith S, Ibrahim MI, Ariffin NH, Van Rostenberghe H. A Preliminary Study on the Reliability of the Malay Version of PedsQL™ Family Impact Module among Caregivers of Children with Disabilities in Kelantan, Malaysia. Malays J Med Sci. 2011 Oct;18(4):63-8. PMID: 22589674; PMCID: PMC3328932.
Copy Download .nbib Format: NLM
Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq.

Asian journal of transfusion science

Othman AA, Eissa AA, Markous RD, Ahmed BD, Al-Allawi NA.
PMID: 24678171
Asian J Transfus Sci. 2014 Jan;8(1):32-4. doi: 10.4103/0973-6247.126687.

BACKGROUND AND AIM: Owing to the scarcity of data on hepatitis C virus (HCV) genotypes in Iraq and due to their epidemiological as well as therapy implications, this study was initiated aiming at determining these genotypes in Northern Iraq.MATERIALS...

Cite
Othman AA, Eissa AA, Markous RD, et al. Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq. Asian J Transfus Sci. 2014;8(1):32-4doi: 10.4103/0973-6247.126687.
Othman, A. A., Eissa, A. A., Markous, R. D., Ahmed, B. D., & Al-Allawi, N. A. (2014). Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq. Asian journal of transfusion science, 8(1), 32-4. https://doi.org/10.4103/0973-6247.126687
Othman, Adil A, et al. "Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq." Asian journal of transfusion science vol. 8,1 (2014): 32-4. doi: https://doi.org/10.4103/0973-6247.126687
Othman AA, Eissa AA, Markous RD, Ahmed BD, Al-Allawi NA. Hepatitis C virus genotypes among multiply transfused hemoglobinopathy patients from Northern Iraq. Asian J Transfus Sci. 2014 Jan;8(1):32-4. doi: 10.4103/0973-6247.126687. PMID: 24678171; PMCID: PMC3943142.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 397 entries